Tocopherol is a Novel Treatment for Cancer Related Mucositis

This study has been withdrawn prior to enrollment.
(the PI is no longer work at Hadassah)
Information provided by:
Hadassah Medical Organization Identifier:
First received: September 11, 2005
Last updated: April 7, 2011
Last verified: September 2005
The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the Department of Bone Marrow Transplantation. Mucositis is a major problem in the management of transplant recipients which subjects the patients to the risk of sepsis, need for parenteral nutrition and need of narcotics. We are planning a 2 arm study, comparing 2 safe vitamin E based formulations with placebo.

Condition Intervention Phase
Oral Mucositis
Drug: Tocopherol
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized Double Blind Placebo Controlled Clinical Trial Aim to Assess the Efficacy of Vitamin E Formulation (Tocopherol) in the Treatment of Chemotherapy Induced Stomatitis in Patients Undergoing Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • To evaluate the tolerability and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.

Secondary Outcome Measures:
  • To evaluate the toxicity and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.

Estimated Enrollment: 30
Study Start Date: December 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and non-pregnant and non-lactating females, 18 years of age or older at the time of screening, who are to receive myeloablative agonists with or without total body irradiation (TBI) in preparation for either allogeneic or autologous HSCT. Patients who are to be hospitalized and are expected to remain hospitalized until marrow recovery.
  • Karnofsky performance status of 60 or greater or ECOG performance status of 2 or less.
  • Normal dental examination as assessed by the investigator.

Exclusion Criteria:

  • Clinically significant acute and active oral cavity infection.
  • Patients taking any investigational or other non-approved oral therapy for oral mucositis.
  • Known hypersensitivity to Vitamin E.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00162526

Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Shimon Slavin, MD Hadassah Medical Organization
  More Information

No publications provided Identifier: NCT00162526     History of Changes
Other Study ID Numbers: 270505-HMO-CTIL 
Study First Received: September 11, 2005
Last Updated: April 7, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Digestive System Diseases
Gastrointestinal Diseases
Mouth Diseases
Stomatognathic Diseases
Vitamin E
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Vitamins processed this record on February 11, 2016